Fig. 1

BMNK cell phenotype of AML patients after HSCT. a Frequency of BMNK cells in leukocyte, frequencies of CD56^bright and CD56^dim cells and the ratio of immature to mature NK cells. b Representative plots (top) of CD57⁺, KIRs⁺, CD56^dimKIRs⁺CD57⁺, NKG2A⁺ BMNK cells from healthy controls (HD, N = 12), complete remission patients (CR, N = 30) and relapse patients after HSCT (Relapse, N = 30), and frequencies (bottom) of CD57⁺, KIRs⁺, CD56^dimKIRs⁺CD57⁺. c Representative plots (left) and the expression level (right) of NKG2A, TIM-3,TIGIT and PD-1on NK cells from healthy controls (HD, N = 12), complete remission patients (CR, N = 30) and relapsed patients (Relapse, N = 30) after HSCT (right). d Representative plots (left) and summary data showing the IFN-γ production and degranulation capacity of CD107a of BM NK cells after treatment with K562 cells for 4 h. CR, N = 26; relapse, N = 26; HD, N = 12 (right). e The 7AAD⁺Annexin V⁺ cells (apoptotic leukemia cells) induced by BMNK cells sorted from healthy donors(HD) (N = 3), CR (N = 3) or relapse (N = 3)